Oncotarget

Addendum:

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss

PDF  |  How to cite

Oncotarget. 2023; 14:747-747. https://doi.org/10.18632/oncotarget.28481

Metrics: PDF 490 views  |   ?  

Maroun Bou Zerdan1, Prashanth Ashok Kumar2, Elio Haroun3, Nimisha Srivastava2, Jeffrey Ross4,5 and Abirami Sivapiragasam2

1Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
2Department of Internal Medicine, Division of Hematology Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
3SUNY Upstate Medical University, Syracuse, NY 13210, USA
4Foundation Medicine, Inc., Morrisville, NC 27560, USA
5Departments of Pathology and Urology, SUNY Upstate Medical University, Syracuse, NY 13210, USA

Published: August 7, 2023

Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: No external funding was provided for this research.

Original article: Oncotarget. 2023; 14:178-187. DOI: https://doi.org/10.18632/oncotarget.28376.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28481